{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:46:42Z","timestamp":1791283602112,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02522-8","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T09:02:04Z","timestamp":1727946124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment"],"prefix":"10.1186","volume":"21","author":[{"given":"Wencong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiurong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"1","key":"2522_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284\u2013306.","journal-title":"Hepatology"},{"issue":"3","key":"2522_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"CL Lin","year":"2023","unstructured":"Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29(3):605\u201322.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"2522_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/jvh.13471","volume":"28","author":"A Song","year":"2021","unstructured":"Song A, Wang X, Lu J, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2021;28(4):601\u201312.","journal-title":"J Viral Hepat"},{"issue":"4","key":"2522_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/jcm11041126","volume":"11","author":"SP Kaur","year":"2022","unstructured":"Kaur SP, Talat A, Karimi-Sari H, et al. Hepatocellular carcinoma in hepatitis B virus-infected patients and the role of hepatitis B surface antigen (HBsAg). J Clin Med. 2022;11(4):1126.","journal-title":"J Clin Med"},{"issue":"1","key":"2522_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.16659","volume":"55","author":"A Vittal","year":"2022","unstructured":"Vittal A, Sharma D, Hu A, et al. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022;55(1):8\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"2522_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/apt.13630","volume":"43","author":"YC Chen","year":"2016","unstructured":"Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. Aliment Pharmacol Ther. 2016;43(12):1311\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2522_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"4","key":"2522_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"6","key":"2522_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958\u201372.","journal-title":"Hepatol Int"},{"issue":"5","key":"2522_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jvh.13792","volume":"30","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xing M, Sun W, et al. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: a real-world analysis. J Viral Hepat. 2023;30(5):427\u201336.","journal-title":"J Viral Hepat"},{"issue":"6","key":"2522_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/infdis\/jiv547","volume":"213","author":"KH Liang","year":"2016","unstructured":"Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon Is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2016;213(6):966\u201374.","journal-title":"J Infect Dis"},{"issue":"3","key":"2522_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","volume":"75","author":"MG Martinez","year":"2021","unstructured":"Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75(3):706\u201317.","journal-title":"J Hepatol"},{"issue":"17","key":"2522_CR13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802\u201313.","journal-title":"JAMA"},{"issue":"1","key":"2522_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","volume":"13","author":"G Wang","year":"2021","unstructured":"Wang G, Guan J, Khan NU, et al. Potential capacity of interferon-alpha to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog. 2021;13(1):22.","journal-title":"Gut Pathog."},{"issue":"1","key":"2522_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","volume":"68","author":"TC Yip","year":"2018","unstructured":"Yip TC, Wong GL, Wong VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2018;68(1):63\u201372.","journal-title":"J Hepatol"},{"issue":"5","key":"2522_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00535-015-1128-2","volume":"51","author":"WK Seto","year":"2016","unstructured":"Seto WK, Cheung KS, Wong DK, et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol. 2016;51(5):487\u201395.","journal-title":"J Gastroenterol"},{"issue":"12","key":"2522_CR17","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1136\/gutjnl-2019-320015","volume":"69","author":"MA Kim","year":"2020","unstructured":"Kim MA, Kim SU, Sinn DH, et al. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut. 2020;69(12):2214\u201322.","journal-title":"Gut"},{"issue":"Suppl 1","key":"2522_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","volume":"26","author":"MH Li","year":"2019","unstructured":"Li MH, Yi W, Zhang L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat. 2019;26(Suppl 1):32\u201341.","journal-title":"J Viral Hepat"},{"issue":"1","key":"2522_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hep4.1436","volume":"4","author":"AS Lok","year":"2020","unstructured":"Lok AS, Zoulim F, Dusheiko G, et al. Durability of hepatitis b surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B. Hepatol Commun. 2020;4(1):8\u201320.","journal-title":"Hepatol Commun"},{"issue":"7","key":"2522_CR20","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/liv.14801","volume":"41","author":"CQ Pan","year":"2021","unstructured":"Pan CQ, Li MH, Yi W, et al. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int. 2021;41(7):1498\u2013508.","journal-title":"Liver Int"},{"key":"2522_CR21","doi-asserted-by":"publisher","first-page":"1120300","DOI":"10.3389\/fcimb.2023.1120300","volume":"13","author":"Y Guo","year":"2023","unstructured":"Guo Y, Han J, Zhang Y, et al. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Front Cell Infect Microbiol. 2023;13:1120300.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"2522_CR22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/apt.17670","volume":"58","author":"N Gao","year":"2023","unstructured":"Gao N, Guan G, Xu G, et al. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy. Aliment Pharmacol Ther. 2023;58(10):1086\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2522_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13148-020-00928-z","volume":"12","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Yuan H, Yang G, et al. IFN-alpha confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA. Clin Epigenetics. 2020;12(1):135.","journal-title":"Clin Epigenetics"},{"issue":"6","key":"2522_CR24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/hep.21187","volume":"43","author":"M Bonvin","year":"2006","unstructured":"Bonvin M, Achermann F, Greeve I, et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology. 2006;43(6):1364\u201374.","journal-title":"Hepatology"},{"issue":"4","key":"2522_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/genes9040207","volume":"9","author":"K Bloom","year":"2018","unstructured":"Bloom K, Maepa MB, Ely A, Arbuthnot P. Gene therapy for chronic hbv-can we eliminate cccDNA? Genes (Basel). 2018;9(4):207.","journal-title":"Genes (Basel)."},{"issue":"3","key":"2522_CR26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00535-016-1244-7","volume":"52","author":"A Matsumoto","year":"2017","unstructured":"Matsumoto A, Imaizumi M, Tanaka Y, et al. Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol. 2017;52(3):376\u201384.","journal-title":"J Gastroenterol"},{"issue":"5","key":"2522_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/liv.12980","volume":"36","author":"WK Seto","year":"2016","unstructured":"Seto WK, Tanaka Y, Wong DK, et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int. 2016;36(5):642\u201350.","journal-title":"Liver Int"},{"issue":"9","key":"2522_CR28","doi-asserted-by":"publisher","first-page":"e3308","DOI":"10.1093\/cid\/ciaa807","volume":"73","author":"JH Lee","year":"2021","unstructured":"Lee JH, Lee YB, Cho EJ, Yu SJ, Yoon JH, Kim YJ. Entecavir plus pegylated interferon and sequential hepatitis B virus vaccination increases hepatitis b surface antigen seroclearance: a randomized controlled proof-of-concept study. Clin Infect Dis. 2021;73(9):e3308\u201316.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2522_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12985-024-02344-8","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ren S, Ma L, et al. Peg-IFNalpha combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function. Virol J. 2024;21(1):77.","journal-title":"Virol J."},{"issue":"6","key":"2522_CR30","doi-asserted-by":"publisher","first-page":"ofaa208","DOI":"10.1093\/ofid\/ofaa208","volume":"7","author":"QL Zeng","year":"2020","unstructured":"Zeng QL, Yu ZJ, Shang J, et al. Short-term peginterferon-induced high functional cure rate in inactive chronic hepatitis B virus carriers with low surface antigen levels. Open Forum Infect Dis. 2020;7(6):ofaa208.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2522_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/jcm12010361","volume":"12","author":"F Wu","year":"2023","unstructured":"Wu F, Wang Y, Cui D, et al. Short-term Peg-IFN alpha-2b re-treatment induced a high functional cure rate in patients with HBsAg recurrence after stopping peg-IFN alpha-based regimens. J Clin Med. 2023;12(1):361.","journal-title":"J Clin Med"},{"issue":"1","key":"2522_CR32","doi-asserted-by":"publisher","first-page":"2161254","DOI":"10.1080\/21645515.2022.2161254","volume":"19","author":"S Jiang","year":"2023","unstructured":"Jiang S, Cai M, Zhang Z, et al. The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance. Hum Vaccin Immunother. 2023;19(1):2161254.","journal-title":"Hum Vaccin Immunother"},{"issue":"1 Suppl","key":"2522_CR33","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","volume":"64","author":"A Bertoletti","year":"2016","unstructured":"Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64(1 Suppl):S71\u201383.","journal-title":"J Hepatol"},{"issue":"1","key":"2522_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12072-014-9571-3","volume":"9","author":"MJ van Campenhout","year":"2015","unstructured":"van Campenhout MJ, Janssen HL. How to achieve immune control in chronic hepatitis B? Hepatol Int. 2015;9(1):9\u201316.","journal-title":"Hepatol Int"},{"key":"2522_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coviro.2018.04.002","volume":"30","author":"D Corti","year":"2018","unstructured":"Corti D, Benigni F, Shouval D. Viral envelope-specific antibodies in chronic hepatitis B virus infection. Curr Opin Virol. 2018;30:48\u201357.","journal-title":"Curr Opin Virol"},{"issue":"2","key":"2522_CR36","doi-asserted-by":"publisher","first-page":"2259003","DOI":"10.1080\/22221751.2023.2259003","volume":"12","author":"S Yin","year":"2023","unstructured":"Yin S, Wan Y, Issa R, et al. The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment. Emerg Microbes Infect. 2023;12(2):2259003.","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"2522_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354.","journal-title":"J Hepatol"},{"issue":"2","key":"2522_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2019.04.020","volume":"18","author":"Y Wu","year":"2020","unstructured":"Wu Y, Liu Y, Lu J, et al. Durability of Interferon-induced hepatitis B surface antigen seroclearance. Clin Gastroenterol Hepatol. 2020;18(2):514\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2522_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","volume":"18","author":"AS Alawad","year":"2020","unstructured":"Alawad AS, Auh S, Suarez D, Ghany MG. Durability of spontaneous and treatment-related loss of hepatitis B s antigen. Clin Gastroenterol Hepatol. 2020;18(3):700\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2522_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.virs.2022.03.001","volume":"37","author":"M Li","year":"2022","unstructured":"Li M, Sun F, Bi X, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virol Sin. 2022;37(3):390\u20137.","journal-title":"Virol Sin"},{"issue":"3","key":"2522_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.gendis.2022.03.003","volume":"10","author":"Z Shi","year":"2023","unstructured":"Shi Z, Zheng H, Han M, et al. Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: a real-world data from Electronic Health Record. Genes Dis. 2023;10(3):1019\u201328.","journal-title":"Genes Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02522-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T10:03:17Z","timestamp":1727949797000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02522-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2522"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02522-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted approval by the Ethics Committee of Tongji Hospital (TJ-IRB20220929) of Huazhong University of Science and Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing conflicts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}